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It is often surprisingly diﬃcult to tell whether a treatment for Alzheimer’s disease is eﬀective. Biomarkers might oﬀer the potential
of a quantiﬁable objective measure of treatment eﬀectiveness. This paper suggests several criteria by which biomarkers might be
evaluated as outcomes measures. Theseinclude biological plausibility, statistical signiﬁcance, dosedependence, convergence across
measures, and replicability. If biomarkers can meet these criteria, then, pending regulatory approval, they may have a role in the
evaluation of treatment eﬀectiveness in Alzheimer’s disease. If not, their usefulness may be in supplementing, but not supplanting,
clinical proﬁles of treatment eﬀects.
For a compound to be a demonstrably eﬀectivetreatmentfor
Alzheimer’s disease two broad conditions must be met: ﬁrst,
the compound must be eﬀective, and, second, it must
be tested in a way which allows that eﬀectiveness to be
demonstrated. As formidably diﬃcult as the ﬁrst challenge
is, it also can be surprisingly tricky to show that any treat-
ment for Alzheimer’s disease that falls short of cure oﬀers
therapeutic potential. Even the tried-and-true Alzheimer’s
Disease Assessment Scale—Cognitive Subscale (ADAS-Cog)
misclassiﬁes important clinical change—typically overesti-
mating decline [1]—so that more than twenty years into
the modern era in dementia therapeutics, a recent consensus
reporthascalledforanewmultidimensionalmeasureforuse
in dementia drug trials [2].
I n t ot h i sb r e e c hb i o m a r k e r ss e e mp o i s e dt os t e p .I ng e n -
eral, a biomarker for dementia is the term given to “measur-
able biological characteristics that can either serve as indica-
torsofnormalorpathogenicprocessesinthebody,orastools
totrackpharmacologicalresponsestotherapeuticdrugs”[3].
Astheaccompanyingpapersinthisissueamplydemonstrate,
there are a host of sometimes ingenious measures that might
be employed as biomarkers. Of particular interest is that
some such measures might be detectable years before clinical
dementia is present; in this way, they serve as targets for ther-
apy, such that with successful treatment the manifestations
of Alzheimer’s disease are either attenuated or even absent.
The challenges to achieving this heroic goal are formidable,
requiring an advanced understanding of Alzheimer’s disease
pathophysiology, and the ability of candidate biomarkers to
be measured and tracked over time. In addition to these and
other important technical and scientiﬁc challenges, however,
aresomeconceptualconsiderationswhichneedtobeconsid-
ered, and which are the subject of this paper. It will discuss
criteria for a biomarker to be used as a measure of treatment
eﬀects and some challenges in regard to each criterion. The
purpose is not to discourage the very signiﬁcant advances
possible in the implementation of the biomarker agenda, but
to lay out some of what needs to be addressed if the full value
istoberealized.Thesecriteriaforwhetherabiomarkermight
be used to measure treatment eﬀects are based on criteria for
making inferences about clinical meaningfulness [4] them-
selves based on the Bradford-Hill criteria for establishing
whether an association is causal [5]. Brieﬂy, these criteria
are: the biomarkers should, on biological grounds, plausibly
be related to Alzheimer’s disease; it should be statistically
signiﬁcant; it should show dose-dependent eﬀects; it should
show convergence with related measures; it should be
replicable. Next, we consider each in a little more detail.
The biomarker should be biologically plausible. This
criterion is likely to be the weakest, on three grounds. First,2 International Journal of Alzheimer’s Disease
it will almost always be met for any biomarker, because a
theoretical basis for its measurement will likely be the basis
on which it is investigated in the ﬁrst place. Second, as
it is inherent that our understanding of biology is always
contingent, and that data to the contrary will always trump
a good hypothesis, no biologically plausible explanation is
likely to withstand data to the contrary. Even so, the role of
clinical trials in enhancing our understanding of the biology
must be stressed. For example, successive failures of gamma-
secretase inhibitors have given credence to the proposition
that a new generation of such compounds must be selective
for inhibiting a-beta in comparison with Notch signaling
endpoints [6]. The ability to conﬁrm this in human studies
willhelpsecurethisunderstandingoftheunderlyingbiology.
Even so, a particular challenge to any argument about the
biological plausibility of any single candidate biomarker is
this. Dementia is highly age associated. As people grow older,
they are more likely to have more than one thing wrong with
them, and these cumulative small eﬀects can add up to make
dementia more likely [7]; in like manner, we see in older
adults, many causes of dementia existing in a single brain
[8, 9]. The inﬂuence of cooccurring dementia pathologies on
diseaseexpressioncanposeaheavyburdenonanyprediction
which might rest on just one biomarker.
The association between the biomarker and disease
expression should be statistically signiﬁcant. On its face,
this seems like a reasonable enough criterion and it might
w e l lp r o v et ob et r u ei np r a c t i c e .B u tw h a ti fi tt u r n so u t
that no single biomarker on its own will be suﬃciently
persuasive? This view is in fact supposed by the Dubois
criteria being proposed for the diagnosis of dementia [10].
These new criteria propose several candidate biomarkers
be measured, and they suggest increased predictive power
will be the case when more biomarkers are present. Note,
however, that a recent review suggests that most biomarkers
have poor positive predictive value used on their own, and
in established clinical disease are inferior to memory testing
[11]. How they will work out in combination, especially to
track preclinical or “pathophysiological” Alzheimer disease,
when clinical symptoms are expected largely to be lacking,
will be an important research question. Will it be the case
that altering biomarkers of amyloid deposition will alter
biomarkers of neurodegeneration to in turn alter clinical
disease expression [12]? With regard to established disease,
biomarkers that change as disease progresses, such as func-
tional and metabolic markers detected by task-dependent
activation on functional MRI and 18F-ﬂuorodeoxyglucose
PET, may be candidates for demonstrating statistically
signiﬁcant treatment eﬀects [13].
The biomarker should show a dose-dependent eﬀect.
This too seems like an indubitable proposition. Not for
nothing is the metaphor of “treating cholesterol” so top of
mind at many biomarker discussions. Jason Karlawish of the
University of Pennsylvania summed up the situation well
in his presentation to the 11th International Congress of
Alzheimer’sDiseaseplenaryaddressinHonoluluinJuly2010
[14]. There he described the change in the conceptualization
of Alzheimer’s disease from the leading cause of dementia
to a risk state. This new risk state amounts to Alzheimer’s
disease without dementia, which is proposed to be identiﬁed
by a series of abnormalities detected by any or some
combination of neuroimaging, serum, or cerebrospinal ﬂuid
abnormalities [12] .T h ea n a l o g yw o u l db em u c hl i k et h e
risk of stroke, which is now indicated by an elevation
in serum cholesterol. Following the biomarkers model,
satisfactory treatment of Alzheimer disease would thereby
be demonstrated by altering the level of the biomarker in
a favourable direction, although this would be expected
to hold only for biomarkers that might be expected to
change with treatment—that is, those that were useful for
tracking and not just diagnosis. Recent experience with an
increase in hippocampal volumes in nondemented older
adults who enrolled in an exercise program, compared to
continued to decline to those in a sham intervention arm,
is perhaps an exciting hint at how a tracking measure might
work [15]. Such an eﬀect corresponds well with established
work which demonstrated that AD patients with faster
cognitive deterioration tend to have greater hippocampal
atrophy rates [13, 16]. Likewise, dose-dependence will itself
depend on the biomarker and the stage of the patient being
treated. For example, in a trial in people with established
mild cognitive impairment, amyloid biomarkers might be
expected largely to have plateaued whereas an impact on
medial temporal atrophy might be postulated for a disease-
modifying treatment.
This hope for successful treatment of dementia being
reduced to successful treatment of laboratory or imaging
tests, has not gone unnoticed by the pharmaceutical and
diagnosis industries. These industries have invested hun-
dreds of millions of dollars in the “preliminary validation
phase” studies of biomarkers, with the notion that the bio-
markers need to be tight against clinical outcomes. But
even here there is need for further questioning. If there is
one theory that the traditional neuropathological studies
have taught us, it is that the correlation between plaques
and tangles and disease expression is modest when series
include cognitively intact older adults [6, 7, 17, 18]. Whether
we should expect more of contemporary biomarkers in
living patients is an untested proposition. Recent experience
with any amyloid-β1−42 biomarker for prodromal AD/mild
cognitive impairment illustrates the problem. In detailed
simulations based on estimates from the Alzheimer’s Disease
Neuroimaging Initiative, even though patients with prodro-
mal AD who also had the biomarker (in their cerebrospinal
ﬂuid) shared both more impairment at baseline and more
cognitive decline, they also showed more variability in out-
comes [19]. In other words, the dimensionality of dementia
was not reduced by the addition of biomarkers, even though
this was an explicit part of the rationale for their use in
clinical trials, as was the hope that treatment eﬀectiveness
could be demonstrated through biomarker change [20]. Also
in pragmatic terms, this means that adding the biomarker
did not improve the eﬃciency of the trial, in that this did not
increase power or improve sample sizes.
The criterion of convergence of measures means that if
a biomarker were to successfully predict dementia, then it
should be reﬂected in more than one dementia measure. For
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measured by the ADAS-Cog might reasonably be expected—
at least in the preliminary validation phase—to predict
decline in at least some of function, behaviour, quality of
life, and caregiver measures. It might also expect to correlate
with adverse change in more than one biomarker, on the
assumption that dementia is a complex disease state. As
with the other criteria, however, there might well need to
be nuance in the interpretation. For example, decline in
measures will reﬂect their time frame. If cognitive decline
precedes functional impairment, following a preventive
strategy, measures might not converge for some time. In
addition, if a given biomarker is associated with some disease
aspects more than others, convergence of measures might be
modest.
As a ﬁnal criterion, any result about biomarkers must be
replicable. As always, this is the highest scientiﬁc standard,
especially when replicated by entirely independent groups.
Given the proprietary nature of much of the biomarkers
enterprise, what constitutes independent replication may be
a standard short of entirely independent groups. Even so,
every eﬀort should be made to achieve this standard. Usually
study design consideration—double-blinding being chief
amongst them—will constitute the necessary minimum.
This inventory of criteria for using biomarkers to
measure treatment eﬀects has focused on how to look. We
also must consider what to look for; the recognition of
Alzheimer’s disease as a complex state has implications in
this regard. Chief amongst these is that short of a cure,
treatment for Alzheimer’s disease will not be the same as
having no cognitive impairment, or even age-associated or
age-appropriate cognitive function. Rather, it is likely that
some features of Alzheimer’s disease will be present to only
a trivial extent, others will be more modestly attenuated
and others still might be unaﬀected. Whether this diversity
of disease modifying eﬀects can be captured in a single
biomarker,orabatteryofthem,isapropositionthatremains
to be tested.
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